Prime Medicine (PRME) Operating Expenses (2021 - 2026)

Prime Medicine (PRME) has 6 years of Operating Expenses data on file, last reported at $51.5 million in Q1 2026.

• Quarterly Operating Expenses fell 4.34% year-over-year to $51.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $210.6 million (changed 0.13% YoY) and the FY2025 annual result came in at $213.0 million, up 3.67% from the prior year.
• Operating Expenses climbed to $51.5 million in Q1 2026, from $49.4 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $68.0 million in Q4 2023 to a low of $19.9 million in Q1 2022.
• A 5-year average of $46.5 million and a median of $49.4 million in 2025 frame the typical range for Operating Expenses.
• The widest YoY moves for Operating Expenses: up 203.59% in 2022, down 35.6% in 2022.
• Tracing PRME's Operating Expenses over 5 years: stood at $38.7 million in 2022, then surged by 75.89% to $68.0 million in 2023, then slumped by 31.8% to $46.4 million in 2024, then gained by 6.55% to $49.4 million in 2025, then climbed by 4.17% to $51.5 million in 2026.
• The last three Operating Expenses figures came in at $51.5 million (Q1 2026), $49.4 million (Q4 2025), and $55.2 million (Q3 2025), per Business Quant data.